Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial
Sponsor: Medical University of South Carolina
A PHASE3 clinical study on Post-ERCP Pancreatitis, this trial is completed. The trial is conducted by Medical University of South Carolina and has accumulated 13 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jun 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 8 earlier versions
-
Jul 2022 — Jun 2023 [monthly]
Recruiting PHASE3
-
May 2021 — Jul 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Apr 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Apr 2018 [monthly]
Recruiting PHASE3
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical University of South Carolina
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .